Quetiapine Should NOT Be Used for Insomnia
Quetiapine is not recommended for the treatment of insomnia at any dose, and there is no established "maximum dose" for this indication because it is not FDA-approved for insomnia and major clinical guidelines explicitly advise against its use.
Why Quetiapine Should Be Avoided for Insomnia
The 2019 VA/DoD clinical practice guidelines 1 provide a strong recommendation against using antipsychotics, including quetiapine, for chronic insomnia disorder. The guideline work group found that:
- Evidence supporting quetiapine for insomnia is sparse and unclear, with small sample sizes and short treatment durations
- The evidence is insufficient to determine efficacy
- All antipsychotics, including low-dose quetiapine, cause known harms that outweigh any potential benefits
Specific Harms of Low-Dose Quetiapine
Even at low doses commonly used for insomnia (25-100 mg), quetiapine carries significant risks:
Mortality and Serious Events:
- Increased risk of death in elderly populations with dementia-related psychosis 1
- Recent 2025 data shows 3-fold increased mortality risk compared to trazodone (HR 3.1) in older adults 2
- Increased suicidal tendencies in children, adolescents, and young adults 1
Cognitive and Falls:
- 8-fold increased risk of dementia compared to trazodone (HR 8.1) 2
- 7-fold increased risk of dementia compared to mirtazapine (HR 7.1) 2
- 2.8-fold increased risk of falls compared to trazodone 2
- Next-day impairment in vigilance and driving performance 3
Metabolic Effects:
- Weight gain averaging 4.9 lbs and BMI increase of 0.8 points even at doses ≤200 mg 4
FDA-Approved Dosing (Not for Insomnia)
The FDA label 5 does not include insomnia as an approved indication. Approved indications and their doses are:
- Schizophrenia: 150-750 mg/day (max 750 mg/day)
- Bipolar mania: 400-800 mg/day (max 800 mg/day)
- Bipolar depression: 300 mg/day at bedtime (max 300 mg/day)
What the Research Actually Shows
While some small studies suggest quetiapine 25-100 mg may improve sleep parameters 6, 7, 8, 9, these findings are:
- Based on very small sample sizes
- Short duration (days to weeks)
- Do not assess long-term safety
- Show inconsistent results (e.g., the 2010 RCT 8 with 25 mg failed to reach statistical significance)
The most recent 2026 study 3 found that while 50 mg quetiapine modestly reduced AHI and improved sleep efficiency, it significantly impaired next-day vigilance and driving performance.
Recommended Alternatives
Based on the same VA/DoD guidelines 1 and ACP guidelines 10:
First-line: Cognitive behavioral therapy for insomnia (CBT-I)
If pharmacotherapy needed:
- Nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon) at lowest effective dose for shortest duration
- Low-dose doxepin (3-6 mg) - FDA-approved for insomnia
- Suvorexant (orexin receptor antagonist) 15-20 mg 10
Not recommended: Benzodiazepines, trazodone (insufficient evidence), antihistamines (tolerance develops in 3-4 days), or antipsychotics including quetiapine
Clinical Bottom Line
There is no safe or appropriate dose of quetiapine for insomnia. The practice of prescribing 25-100 mg "off-label" for sleep is not supported by high-quality evidence and exposes patients to serious harms including increased mortality, dementia, falls, and next-day functional impairment—risks that far outweigh any modest sleep benefits.